WithdrawnPhase 2NCT01892644

Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome

Studying Hereditary Hemochromatosis

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Haukeland University Hospital
Principal Investigator: Rune J Ulvik, MD, PhD
Dept. of Clinical Science and Lab. of Clinical Biochemistry, Univ. of Bergen and Haukeland University Hospital, Bergen, N5021, Norway
Intervention: Deferasirox(drug)
Eligibility: 18-80 years · All sexes
Timeline: 2013 – 2017

Study locations (1)

Haukeland University Hospital, Clinical Trial Unit, Bergen, Norway

Collaborators

Novartis

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01892644 on ClinicalTrials.gov

← Back to all trials